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LETTERS TO THE EDITOR 619are needed to guide treatment selection including which patients
could benefit from CTLA4-ligand–targeted immunomodulation
versus HSCT, optimal timing of HSCT, and long-term outcome
post-HSCT.
Medac, GmbH provided treosulfan for the study in the United States.
Mary A. Slatter, MDa,b
Karin R. Engelhardt, PhDa
Lauri M. Burroughs, MDc,d
Peter D. Arkwright, DPhile
Zohreh Nademi, PhDa,b
Suzanne Skoda-Smith, MDc
David Hagin, PhDc
Alan Kennedy, PhDf
Dawn Barge, PhDg
Terence Flood, MDa
Mario Abinun, PhDa,b
Robert F. Wynn, MDe
Andrew R. Gennery, MDa,b
Andrew J. Cant, MDa,b
David Sansom, PhDf
Sophie Hambleton, DPhila,b
Troy R. Torgerson, MDc
From aGreat North Children’s Hospital, Newcastle upon Tyne Hospitals, NHS Founda-
tion Trust, Newcastle upon Tyne, United Kingdom; bthe Primary Immunodeficiency
Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle
upon Tyne, United Kingdom; cthe University of Washington and Seattle Children’s
Hospital, Seattle, Wash; dFred Hutchinson Cancer Research Center, Seattle, Wash;
ethe University of Manchester, Royal Manchester Children’s Hospital, Manchester,
United Kingdom; fthe UCL Institute of Immunity and Transplantation, Royal Free
Hospital, London, United Kingdom; and gthe Regional Immunology Laboratory,
Newcastle upon Tyne, United Kingdom. E-mail: mary.slatter@nuth.nhs.uk.
Funding from the National Institutes of Health (NIH) contributed to this work (grant nos.
NIH R13 AI094943, NIH U54 AI082973, and NIH P01 HL122173). One of the US
patients was enrolled in a clinical trial supported in part by the NIH (grant P01
HL122173), as well as research funding from Medac, GmbH (Hamburg, Germany).
Disclosure of potential conflict of interest: L. M. Burroughs receives research funding
from the National Institute of Health (NIH). S. Hambleton receives research funding
from the Sir Jules Thorn Trust. T. R. Torgerson serves as a consultant for Baxalta Bio-
sciences, CSL Behring, and ADMABiosciences; receives research funding from Bax-
alta Biosciences, CSL Behring, and the NIH; and receives payments for educational
developments from Baxalta Biosciences, CSL Behring, Questor Pharmaceuticals, and
the Robert Wood Johnson Foundation. The rest of the authors declare that they have
no relevant conflicts of interest.
REFERENCES
1. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune
dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Science 2014;345:1623-7.
2. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal
dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat
Med 2014;20:1410-6.
3. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient
mice is mediated by costimulation-dependent activation of CD41 T cells.
Immunity 1997;7:885-95.
4. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous
variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81.
5. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect
of amino acid substitutions and indels. PLoS One 2012;7:e46688.
6. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods 2014;11:361-2.
7. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al.
Plymorphism phenotyping v2. Nat Methods 2010;7:248-9.
8. Niroula A, Urolagin S, Vihinen M. PON-P2: Prediction method for fast and
reliable identification of harmful variants. PLoS ONE 2015;10:e0117380.
9. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general
framework for estimating the relative pathogenicity of human genetic variants.
Nat Genet 2014;46:310-5.
10. Snowden JA, Pearce RM, Lee J, Kirkland K, Gilleece M, Veys P, et al; BSBMT
Clinical Trials Committee. Haematopoietic stem cell transplantation (HSCT) insevere autoimmune diseases: analysis of UK outcomes from the British Society
of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. Br J
Haematol 2012;157:742-6.
11. Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival
after unrelated donor bone marrow transplantation in children with primary
immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005;
105:879-85.
12. Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J, et al.
Treosulfan-based conditioning and hematopoietic cell transplantation for
nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow
Transplant 2014;20:1996-2003.
13. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al.
AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss
and immune dysregulation responsive to abatacept therapy. Science 2015;349:
436-40.
Available online April 18, 2016.
http://dx.doi.org/10.1016/j.jaci.2016.01.045A novel genomic inversion in
Wiskott-Aldrich–associated
autoinflammationTo the Editor:
Wiskott-Aldrich syndrome (WAS) is an X-linked disorder
characterized by thrombocytopenia, eczema, and immunodefi-
ciency. Up to 70% of patients with WAS present with at least 1
autoimmune or autoinflammatory episode, and many of them
suffer from recurrent or multiple events.1-3 IL-1 new-generation
blockers have been used in patients exhibiting clinical symptoms
compatible with an autoinflammatory condition,4 but have not
been reported in WAS. Here, we describe a patient with WAS
with a peculiar large genomic inversion presenting with multiple
manifestations of immune dysregulation, in whom autoinflamma-
tory manifestations improved after the use of anakinra (IL-1 re-
ceptor antagonist, Kineret).
A 11.6-year-old boy was referred to our center for suspected
immunodeficiency. The patient presented with a history of
microthrombocytopenia since birth and eczema in the first years
of life, suggestive of WAS. Analysis of WAS protein (WASp)
expression was reported abnormal, but Sanger sequencing on
DNA did not reveal mutations. From 1.5 years of age he
underwent recurrent episodes of postinfectious vasculitis of the
lower limbs and arthritis. At 7.5 years, he presented with a
bilateral pneumonia that triggered Schonlein-Henoch purpura
with fever and arthritis, managed with oral steroids. Subse-
quently, a nephritic-nephrotic syndrome was treated with antihy-
pertensive treatment and high-dose corticosteroids (CCS), with
partial response. Cyclosporin A (CyA) and CCS led to remission
of renal disease, which relapsed after CyA was stopped.
Intravenous high-dose CCS and anti-CD20 mAb did not lead to
substantial improvement. CyA and low-dose prednisone were
restarted with partial benefit. However, the patient experienced
varicella zoster reactivation on his half-right-face, with sequelae
to the right eye (anterior and posterior uveitis with acute retinitis)
requiring a vitrectomy, and severe impairment of visual function.
An anterior uveitis at the left eye was treated with steroids. At the
age of 9.8 years, he developed clinical and histological features of
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well as arthritis and histologically confirmed vasculitis and
eventually pyoderma gangrenosum (PG) on the hips, buttocks,
and upper and lower limbs. Crohn disease was not responsive to
infliximab, thalidomide, cyclophosphamide, or high-dose intra-
venous steroids, while adalimumab (Humira) resulted in an initial
benefit (see Table E1 in this article’s Online Repository at www.
jacionline.org). The patient presented with fistulas and perianal
abscesses when he was 10.7 years old and he underwent several
fistulectomies and removal of granulation tissue in the perianal
area by ‘‘cone-like technique.’’ For the poor control of the entero-
colitis, a subtotal colectomy with terminal ileostomy was per-
formed at age 11 years.
When the patient was referred to our center, he was on
adalimumab and low-dose CCS with a good control of bowel
disease, but still showed severe manifestations of PG on the upper
limbs and in the perianal area (Fig 1, A; see Table E2 in this arti-
cle’s Online Repository at www.jacionline.org). His parents
signed informed consent for research investigations (protocol
Tiget06).
Because of the strong suspicion of WAS, whole-genome
sequencing was performed and an inversion of 6kb spanning
from the promoter to the intronic region between exons 7 and 8
was detected (see Fig E1 in this article’s Online Repository at
www.jacionline.org). Specific primers in this region identified
the precise breaking points (see Tables E3 and E4 in this article’s
Online Repository at www.jacionline.org; Fig 2, B). Therearranged allele was present in the patient and his mother,
whereas the patient’s aunt was unaffected (data not shown and
Fig 2, A-C).
RNA analyses showed an aberrant transcript produced from the
inverted region (Fig 2, D). WASp expression, analyzed by flow
cytometry (see Fig E2, A, in this article’s Online Repository at
www.jacionline.org), was deeply reduced in peripheral blood
T-, B-, and natural killer lymphocytes and monocytes (data not
shown) while it was undetectable by Western blot performed
with an antibody recognizing the N-terminal portion of WASp
including exons 7 and 8 (Fig E2, B). WASp expression was
restored in the patient’s T-cell line transduced with a lentiviral
vector expressing WASp under the control of the autologous
1.6-kb long promoter5 (Fig E2, C).
The start of low-dose methotrexate (Reumaflex) and the
increase in prednisone led to a moderate improvement in the
PG after 3 months (Fig 1, B), but shortly after the patient under-
went a reactivation of vasculitis and arthritis with systemic
inflammation that was not controlled by multiple immunosup-
pressive and anti-inflammatory drugs.
On the basis of the reported efficacy of IL-1 blockers in the
treatment of autoinflammatory manifestations and of PG,4 ana-
kinra was started as an off-label drug titrating the dose from 1
up to 3 mg/kg/day. This led to a resolution of vasculitis and
arthritis and to a decrease in the inflammation indexes within
few days (Fig 1,D) with dramatic improvement in the PG skin le-
sions during the following 5 months (Fig 1, C).
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autologous gene-corrected hematopoietic stem cells
(clinicaltrials.gov #NCT01515462), mobilized with G-CSF and
plerixafor. Treatment with anakinra was discontinued 48 hours
before mobilization, but was soon restarted because of the in-
crease in white blood cells and inflammation indexes with exacer-
bation of skin lesions, arthralgia, and hematuria, and led again to a
rapid laboratory and clinical remission (data not shown). Notably,
the use of anakinra allowed a successful mobilization with G-CSF
without the occurrence of other autoinflammatorymanifestations.
To our knowledge, this is the first reported case of use of IL-1R
blocker in a patient with WAS, with clinical benefit.
This case is very emblematic for several reasons. Whole-
genome sequencing complemented by specific breakpoint
sequencing allowed the identification of the inversion with
intact exon sequences, elucidating the previous normal genetic
analysis. Complex genomic rearrangements involving inversions
are generally noncanonical gene conversion events6 and could
have occurred in an ancestor allele in the family through a de
novo mutation occurring in the mother.
Autoimmune and autoinflammatory manifestations in patients
with WAS typically present early in life, are often refractory to
therapy, and are associated with a worse clinical prognosis and an
increased risk of developing a malignancy.3,7 Our patient’s autoin-
flammatory manifestations were resistant to several immunosup-
pressive drugs and the use of CyA was associated with a severe
viral complication. Anakinra dramatically improved PG, vasculitis,
and arthritis, showed a good safety profile, and allowed stabiliza-
tion of the patient for definitive treatment. The response to anakinra
suggests that the dysregulation of the innate immune system is
involved in the genesis of autoinflammatory manifestations in pa-
tients with WAS and shows that IL-1 may serve in selected cases
as a target for therapy, avoiding the use of other classes of immuno-
suppressors that can increase the risk for severe infections.
It has been hypothesized that defects in chemotaxis and
podosomes formation in WASp-deficient cells may favor the
onset of autoinflammatory manifestations. In addition, a recent
study in a patient with aggressive PG showed a critical role for
proline-serine-threonine phosphatase interacting protein 1, which
is involved in cytoskeletal regulatory functions through interac-
tion with WASp, in the Pyogenic Arthritis, Pyoderma gangreno-
sum, and Acne syndrome.8 A greater understanding of the role of
WASp in inflammation and of potential pathways that may be tar-
geted therapeutically to modulate immunity in WAS is desirable
to improve the management of the affected patients while waiting
for definitive treatment by stem cell transplantation or gene
therapy.
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Severe combined immunodeficiencies (SCIDs), a group of rare,
inherited conditions characterized by T lymphocytopenia, are
fatal before age 1 year without hematopoietic stem cell trans-
plantation (HSCT). Graft-versus-host disease (GvHD) and
bacteremia cause post-HSCT morbidity and mortality. Early
studies showed that germ-free mice fail to develop GvHD, thus
demonstrating a role for microbiota in GvHD pathogenesis.1 In
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TABLE E1. Summary of treatment of possible autoimmune and autoinflammatory manifestations
Treatment Response
Nephritic/nephrotic syndrome
Steroids Partial
Steroids 1 CyA Remission, then relapse when CyA stopped
Steroids 1 anti-CD20 mAb No
Steroids 1 CyA Partial; infectious complications
Crohn disease
Steroids 1 CyA No
Steroids 1 CyA 1 IVIG No
Steroids 1 CyA 1 infliximab Partial, then relapse
Steroids 1 CyA 1 talidomide No
Steroids 1 cyclophosphamide No
Steroids 1 adalimumab Yes
PG
Steroids 1 dapsone 1 adalimumab No
Steroids 1 dapsone 1 adalimumab 1 MTX Partial
Steroids 1 dapsone 1 anakinra Yes
Arthritis and vasculitis
Steroids 1 CyA Remission, then relapse
Steroids 1 CyA 1 infliximab No
Steroids 1 dapsone 1 adalimumab 1 MTX No
Steroids 1 dapsone 1 anakinra Yes
IVIG, Intravenous immunoglobulin; MTX, methotrexate.
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TABLE E2. Clinical data and significant laboratory findings at WAS diagnosis
Age of onset/diagnosis of disease Neonatal/11.6 y
Genetic analyses (whole-genome sequencing) inv(X)g.5721-11840
Clinical manifestations Microthrombocytopenia
Mild eczema, severe infections, arthritis, vasculitis
Multiple Henoch-Schonlein purpura episodes
Nephritic-nephrotic syndrome, panuveitis
Steroid-resistant Chron enterocolitis
Perianal fistulas and abscesses
PG
Zhu score 5AE1
WBC (3109/L) (normal value, 4.8-10.8 3 109/L) 14.4
Neutrophils (3109/L) (normal value, 1.8-7.7 3 109/L) 12.7
Lymphocytes (3109/L) 1
Platelets range (3109/L) 20-40
MPV (fl) (normal value, 9.1-12.5) 8
CD31 (cells/mL) (normal value, 1000-2100)E2 498
CD31CD41 (cells/mL) (normal value, 500-1300)E2 364
CD31CD81 (cells/mL) (normal value, 220-950)E2 91
CD191 (cells/mL) (normal value, 180-600)E2 101
CD161CD561 (cells/mL) (normal value, 170-670)E2 338
CD41CD45RA1 (cells/mL) (normal value, 320-1000)E3 152
CD41CD45RO1 (cells/mL) (normal value, 230-630)E3 201
CD81CD45RA1 (cells/mL) (normal value, 310-900)E3 159
CD81CD45RO1 (cells/mL) (normal value, 70-390)E3 40
Vb repertoire Polyclonal on CD31
IgG (g/L) (normal value, 7.07-19.19)E4 7.69 (on IVIG supplementation)
IgA (g/L) (normal value, 0.60-2.7)E4 6.68
IgM (g/L) (normal value, 0.61-2.76)E4 0.33
Autoimmunity screening* Negative
Antiplatelets antibody (indirect test) Positive
LLAC Negative
ACA, Anticardiolipin antibody; AMA, antimitochondrial antibody; ANA, antinuclear antibody; ASCA, anti–Saccharomyces cerevisiae antibody; ASMA, anti–smooth muscle
antibody; cANCA, cytoplasmic antineutrophilic cytoplasmic antibodies; ds-DNA, double-strand DNA antibody; ENA, extractable nuclear antibodies; IVIG, intravenous
immunoglobulin; LLAC, lupus-like anticoagulant; LKM1, liver kidney microsomal type 1 antibody; pANCA, protoplasmic antineutrophilic cytoplasmic antibodies; WBC, white
blood cell.
*Including Coombs test, ANA, ENA, AMA, ASMA, anti–LKM1 antibody, anti–dS-DNA antibody, ASCA, cANCA, pANCA, ACA, and anti–b2 glicoprotein antibody.
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TABLE E3. Primers for the detection of DNA inversion
Primer Orientation Sequence PCR cycles
A FOR CTGGAGATACGCCTAGCACA 948C 3 min, 948C 30 s, 558C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
REV TCTGAGGGCTGTAGGGTTTG
B FOR AAGGTGGGCACATGGGTAG 948C 3 min, 948C 30 s, 558C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
REV TCTCAGCAGTGGTCTTTGGA
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TABLE E4. Primers for amplification of cDNA
Region Orientation Sequence PCR cycles
EXON1-4 (279bp) FOR CGAAAATGCTTGACGCTGGC 948C 3 min, 948C 30 s, 54.68C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
REV CTCGTCCTCGTCTGCAAAGT
EXON7-10 (303bp) FOR ACCCAGTGGATTCAAGCATGT 948C 3 min, 948C 30 s, 54.68C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
REV GGACCAGAACGACCCTTGTT
EXON2-7 (449bp) FOR GTCCTACTTCATCCGCCTTTAC 948C 3 min, 948C 30 s, 55.88C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
REV TCTTCCCTGAGCGTTTCTTATC
EXON7-8 (73bp) FOR GTGGATTCAAGCATGTCAGCC 948C 3 min, 948C 30 s, 55.88C 30 s, 728C 1 min 3 40 cycles, 728C 10 min
REV TCTGGGTCGAGGTTGTTCAC
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